Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi 17 Jan 2020
However, in this most recent draft guidance, NICE deemed the current price of Vitrakvi too expensive to be considered for use on the NHS. ... NICE estimates that around 600-700 people have solid tumours with NTRK gene fusion in England.

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata 15 Jan 2020
According to NICE, around 1, 100 people will be eligible for Lynparza through the CDF. ... NICE does not recommend the treatment for relapsed or refractory FLT3-positive acute myeloid leukaemia.

NICE rejects Akcea’s rare inherited disorder drug Waylivra

NICE rejects Akcea’s rare inherited disorder drug Waylivra 6 Jan 2020
Draft guidance deems drug too costly for NHS use. Akcea’s rare inherited disorder drug Waylivra has been handed a resounding no by the UK’s cost-effectiveness watchdog NICE, on ... Although NICE did not raise any concerns about Waylivra’s safety,

NICE knocks back Roche’s Tecentriq for small cell lung cancer

NICE knocks back Roche’s Tecentriq for small cell lung cancer 2 Jan 2020
In  draft guidance, the National Institute for Health and Care Excellence (NICE) says Tecentriq (atezolizumab) in combination with carboplatin and etoposide shouldn’t be made available for untreated extensive-stage SCLC ... being generated –

Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund 28 Nov 2019
Pfizer’s Ibrance has been approved by the National Institute for Health and Care Excellence (NICE) in England through its Cancer Drugs Fund as a second-line treatment for advanced breast ... NICE initially ruled that Ibrance was not a cost-effective

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Infographics